APPLICATION
Application Note
The peptide is used for blocking the antibody activity of anti-BCMA (catalog no. GTX25972). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37ºC.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Tnf Receptor Superfamily Member 17 , Bcm , Bcma , Cd269 , Tnfrsf13A , Tnfrsf17
Background
Members in the TNF superfamily regulate immune responses and induce apoptosis. Two novel members in the TNF family were recently identified and designated BAFF/BLyS/TALL-1/THANK/zTNF4 and April/TALL-2, respectively. BAFF was characterized as a B cell activator since it induced B cell proliferation and immunoglobulin secretion. April regulates immunological and non immunological cell growth. Three receptors, BCMA (for B cell maturation protein), TACI, and BAFF-R, for BAFF were recently identified. BCMA, like TACI, binds BAFF and April. BAFF and its receptors induce B cell development and survival, activate NF-kappaB and c-jun N-terminal kinase, and are involved in B cell associated autoimmune diseases.
Research Area
REFERENCE
There are currently no references for BCMA Peptide (GTX26087). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for BCMA Peptide (GTX26087). Be the first to share your experience with this product.